New Online Social Network, BioMedExperts, to Improve Collaboration Among Medical Researchers

Collexis Holdings, Inc. (OTCBB: CLXS), a leading developer of high definition search and knowledge discovery software, announced the debut of BioMedExperts - the first online social network of its kind to improve collaboration among researchers and therefore advance medical science. Collexis launched the new service with more than 1.4 million pre-generated profiles of its expected users from across 120 countries and expects to grow by another two million profiles over the next few months.

An agreement with Dell Healthcare and Life Sciences helped make BioMedExperts possible. Dell supplied the computer hardware for the service and will help market BioMedExperts.

"The ability for researchers to collaborate across scientific disciplines is becoming more and more critical," said James Coffin, Ph.D., vice president and general manager of Dell Healthcare and Life Sciences. "By connecting biologists, chemists, clinical researchers and other scientists from across the globe, BioMedExperts can play a key role in enabling a new wave of modern science and have tremendous impact on progress in biomedical research."

The new service will allow life sciences professionals to connect with each other, share data, collaborate more efficiently and conduct deep research across thousands of sources.

"Where first generation social networks like Facebook and LinkedIn require users to enter data, BioMedExperts is a life science open platform that goes to the next level – it continuously captures the research activity of experts worldwide, serving as a definitive source to identify relationships to others within the community, either by topic or geography," said Bill Kirkland, CEO of Collexis. When researchers log on to the service, which is entirely free, they will have access to approximately 12 million pre-established network connections, automatically generated from more than 6 million scientific publications from 6,500 journals. BioMedExperts encompasses almost every published researcher in the biomedical sciences field worldwide.

Searching by name, keyword or location, scientists can quickly see their own "network" of co-authors ...and even co-authors of their co-authors. The site makes it easy for researchers and scientists to analyze all associated professional connections within the network as well as find new potential research partners, co-authors, etc.

BioMedExperts includes tools that allow users to:

  • Search the network of profiles and articles by expert name or keyword and analyze the profiles of more than 1.4 million scientists by expertise, region and more
  • Customize their own profiles
  • Communicate with other members of BioMedExperts – users can invite others to their own personal network and email experts from within the entire BioMedExperts community to cultivate and grow professional affiliations
  • Set up article alerts – users can receive alerts on new articles by topic or by name (for example, users can easily track articles published by co-authors

BioMedExperts is based on Collexis' proprietary Fingerprint technology, an enterprise research tool that serves as the basis of search and retrieval solutions for such leading organizations as Harvard University, Johns Hopkins, the Mayo Clinic and The National Institutes of Health.

Kirkland added that BioMedExperts is the first in a series of professional social networks that the company plans to introduce over the next couple of years that utilizes the proprietary technology.

For further information, please visit:
http://www.biomedexperts.com

About Collexis Holdings, Inc.
Named a Trend-Setting product of 2007 by KMWorld, Collexis Holdings, Inc., a leading developer of high definition search and knowledge discovery software since 1999, is headquartered in Columbia, South Carolina (USA), with operations in Geldermalsen, The Netherlands and Cologne, Germany. Collexis' proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis' current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Merck & Co.; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. For more information, please visit www.collexis.com.

Most Popular Now

Sustained cellular immune dysregulation in individ…

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, espe...

New virtual screening strategy identifies existing…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, c...

Pfizer and BioNTech to supply the U.S. with 100 mi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the compan...

European Commission authorizes COVID-19 vaccine Mo…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Commission has granted a cond...

An in vitro study shows Pfizer-BioNTech COVID-19 v…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB...

Serum Institute of India obtains emergency use aut…

AstraZeneca's COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the act...

CureVac and Bayer join forces on COVID-19 vaccine …

Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines b...

New findings help explain how COVID-19 overpowers …

Seeking to understand why COVID-19 is able to suppress the body's immune response, new research from the USC Leonard Davis School of Gerontology suggests that mitochondri...

China grants conditional market approval for Sinop…

The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, C...

Novavax announces initiation of PREVENT-19 pivotal…

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVEN...

AstraZeneca's COVID-19 vaccine authorised for emer…

AstraZeneca's COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 Vaccine, to the 2...